Communiqués SANA AB

Actions

SANION

SE0005794617

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
9,710 ^SEK	-1,12%		-2,90%	-54,20%

24/09	Saniona finalise la toxicologie et la CMC pour SAN2465 – dépôt de la demande d’IND attendu en octobre	FW
24/09	Saniona AB (publ) achève les études de toxicologie et de chimie, fabrication et contrôles (CMC) pour SAN2465, permettant le dépôt d’une demande d’IND	CI

Communiqués

24/09	Saniona completes toxicology and CMC studies for SAN2465, enabling IND submission by October 2026	AQ
07/09	Saniona (Q2 review): With focus into the clinic	AQ
01/09	Saniona’s platform has delivered for others – now it delivers for itself	AQ
27/08	Saniona publishes its interim report for the second quarter of 2026	AQ
20/08	Invitation to Saniona Q2 investor call on 27 August 2026	AQ
18/08	Saniona on the equity and milestone upside in the AstronauTx deal	AQ
10/08	AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration	AQ
23/06	Saniona: Our take on the SAN2668 R&D day	AQ
11/06	Three shots on goal: Saniona prepares to enter the clinic	AQ
04/06	Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies	AQ
28/05	Saniona (Q1 Review): Setting up for the long run	AQ
27/05	Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026	AQ
26/05	SANA : Interim Report Q1 2026	PU
26/05	Saniona publishes its interim report for the first quarter of 2026	AQ
20/05	Invitation to Saniona Q1 investor call on 26 May 2026	AQ
30/04	Saniona publishes its Annual Report for 2025	AQ
27/04	SANA : The board's statement pursuant to Chapter 19, Section 22 of the Swedish companies Act	PU
24/04	SANA : Notice of annual shareholders' meeting 2026	PU
24/04	SANA : Proposal for resolution on LTI 2026	PU
24/04	SANA : Notice of Saniona AB annual shareholders' meeting	PU
24/04	Notice of Saniona AB annual shareholders’ meeting	AQ
12/03	Saniona enters clinical execution phase following transformational year	AQ
12/03	Meet Saniona at several conferences during the spring	AQ
03/03	Saniona (Q4 review): Moving forward nicely	AQ
26/02	Saniona publishes its year-end report for 2025	AQ